Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo

Hongbiao Huang, Yuning Liao, Ningning Liu, Xianliang Hua, Jianyu Cai, Changshan Yang, Huidan Long, Chong Zhao, Xin Chen, Xiaoying Lan, Dan Zang, Jinjie Wu, Xiaofen Li, Xianping Shi, Xuejun Wang, Jinbao Liu

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Inhibition of proteasome-associated deubiquitinases (DUBs) is emerging as a novel strategy for cancer therapy. It was recently reported that auranofin (Aur), a gold (I)-containing compound used clinically to treat rheumatoid arthritis, is a proteasome-associated DUB inhibitor. Disulfiram (DSF), an inhibitor of aldehyde dehydrogenase, is currently in clinical use for treating alcoholism. Recent studies have indicated that DSF can also act as an antitumor agent. We investigated the effect of combining DSF and Aur on apoptosis induction and tumor growth in hepatoma cancer cells. Here we report that (i) the combined treatment of Aur and DSF results in synergistic cytotoxicity to hepatoma cells in vitro and in vivo; (ii) Aur and DSF in combination induces caspase activation, endoplasmic reticulum (ER) stress, and reactive oxygen species (ROS) production; (iii) pan-caspase inhibitor z-VAD-FMK could efficiently block apoptosis but not proteasome inhibition induced by Aur and DSF combined treatment, and ROS is not required for Aur+DSF to induce apoptosis. Collectively, we demonstrate a model of synergism between DSF and proteasomeassociated DUB inhibitor Aur in the induction of apoptosis in hepatoma cancer cells, identifying a potential novel anticancer strategy for clinical use in the future.

Original languageEnglish (US)
Pages (from-to)2796-2808
Number of pages13
JournalOncotarget
Volume7
Issue number3
DOIs
StatePublished - 2016
Externally publishedYes

Fingerprint

Auranofin
Disulfiram
Aldehyde Dehydrogenase
Pharmaceutical Preparations
Neoplasms
Proteasome Endopeptidase Complex
Apoptosis
Hepatocellular Carcinoma
Reactive Oxygen Species
Endoplasmic Reticulum Stress
Caspase Inhibitors
In Vitro Techniques
Deubiquitinating Enzymes
Caspases
Gold
Antineoplastic Agents
Alcoholism
Rheumatoid Arthritis

Keywords

  • Anticancer strategy
  • Auranofin
  • Deubiquitinase inhibitor
  • Disulfiram

ASJC Scopus subject areas

  • Oncology

Cite this

Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo. / Huang, Hongbiao; Liao, Yuning; Liu, Ningning; Hua, Xianliang; Cai, Jianyu; Yang, Changshan; Long, Huidan; Zhao, Chong; Chen, Xin; Lan, Xiaoying; Zang, Dan; Wu, Jinjie; Li, Xiaofen; Shi, Xianping; Wang, Xuejun; Liu, Jinbao.

In: Oncotarget, Vol. 7, No. 3, 2016, p. 2796-2808.

Research output: Contribution to journalArticle

Huang, H, Liao, Y, Liu, N, Hua, X, Cai, J, Yang, C, Long, H, Zhao, C, Chen, X, Lan, X, Zang, D, Wu, J, Li, X, Shi, X, Wang, X & Liu, J 2016, 'Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo', Oncotarget, vol. 7, no. 3, pp. 2796-2808. https://doi.org/10.18632/oncotarget.6425
Huang, Hongbiao ; Liao, Yuning ; Liu, Ningning ; Hua, Xianliang ; Cai, Jianyu ; Yang, Changshan ; Long, Huidan ; Zhao, Chong ; Chen, Xin ; Lan, Xiaoying ; Zang, Dan ; Wu, Jinjie ; Li, Xiaofen ; Shi, Xianping ; Wang, Xuejun ; Liu, Jinbao. / Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo. In: Oncotarget. 2016 ; Vol. 7, No. 3. pp. 2796-2808.
@article{fad9bb22f1064526b835a52db95f7bec,
title = "Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo",
abstract = "Inhibition of proteasome-associated deubiquitinases (DUBs) is emerging as a novel strategy for cancer therapy. It was recently reported that auranofin (Aur), a gold (I)-containing compound used clinically to treat rheumatoid arthritis, is a proteasome-associated DUB inhibitor. Disulfiram (DSF), an inhibitor of aldehyde dehydrogenase, is currently in clinical use for treating alcoholism. Recent studies have indicated that DSF can also act as an antitumor agent. We investigated the effect of combining DSF and Aur on apoptosis induction and tumor growth in hepatoma cancer cells. Here we report that (i) the combined treatment of Aur and DSF results in synergistic cytotoxicity to hepatoma cells in vitro and in vivo; (ii) Aur and DSF in combination induces caspase activation, endoplasmic reticulum (ER) stress, and reactive oxygen species (ROS) production; (iii) pan-caspase inhibitor z-VAD-FMK could efficiently block apoptosis but not proteasome inhibition induced by Aur and DSF combined treatment, and ROS is not required for Aur+DSF to induce apoptosis. Collectively, we demonstrate a model of synergism between DSF and proteasomeassociated DUB inhibitor Aur in the induction of apoptosis in hepatoma cancer cells, identifying a potential novel anticancer strategy for clinical use in the future.",
keywords = "Anticancer strategy, Auranofin, Deubiquitinase inhibitor, Disulfiram",
author = "Hongbiao Huang and Yuning Liao and Ningning Liu and Xianliang Hua and Jianyu Cai and Changshan Yang and Huidan Long and Chong Zhao and Xin Chen and Xiaoying Lan and Dan Zang and Jinjie Wu and Xiaofen Li and Xianping Shi and Xuejun Wang and Jinbao Liu",
year = "2016",
doi = "10.18632/oncotarget.6425",
language = "English (US)",
volume = "7",
pages = "2796--2808",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "3",

}

TY - JOUR

T1 - Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo

AU - Huang, Hongbiao

AU - Liao, Yuning

AU - Liu, Ningning

AU - Hua, Xianliang

AU - Cai, Jianyu

AU - Yang, Changshan

AU - Long, Huidan

AU - Zhao, Chong

AU - Chen, Xin

AU - Lan, Xiaoying

AU - Zang, Dan

AU - Wu, Jinjie

AU - Li, Xiaofen

AU - Shi, Xianping

AU - Wang, Xuejun

AU - Liu, Jinbao

PY - 2016

Y1 - 2016

N2 - Inhibition of proteasome-associated deubiquitinases (DUBs) is emerging as a novel strategy for cancer therapy. It was recently reported that auranofin (Aur), a gold (I)-containing compound used clinically to treat rheumatoid arthritis, is a proteasome-associated DUB inhibitor. Disulfiram (DSF), an inhibitor of aldehyde dehydrogenase, is currently in clinical use for treating alcoholism. Recent studies have indicated that DSF can also act as an antitumor agent. We investigated the effect of combining DSF and Aur on apoptosis induction and tumor growth in hepatoma cancer cells. Here we report that (i) the combined treatment of Aur and DSF results in synergistic cytotoxicity to hepatoma cells in vitro and in vivo; (ii) Aur and DSF in combination induces caspase activation, endoplasmic reticulum (ER) stress, and reactive oxygen species (ROS) production; (iii) pan-caspase inhibitor z-VAD-FMK could efficiently block apoptosis but not proteasome inhibition induced by Aur and DSF combined treatment, and ROS is not required for Aur+DSF to induce apoptosis. Collectively, we demonstrate a model of synergism between DSF and proteasomeassociated DUB inhibitor Aur in the induction of apoptosis in hepatoma cancer cells, identifying a potential novel anticancer strategy for clinical use in the future.

AB - Inhibition of proteasome-associated deubiquitinases (DUBs) is emerging as a novel strategy for cancer therapy. It was recently reported that auranofin (Aur), a gold (I)-containing compound used clinically to treat rheumatoid arthritis, is a proteasome-associated DUB inhibitor. Disulfiram (DSF), an inhibitor of aldehyde dehydrogenase, is currently in clinical use for treating alcoholism. Recent studies have indicated that DSF can also act as an antitumor agent. We investigated the effect of combining DSF and Aur on apoptosis induction and tumor growth in hepatoma cancer cells. Here we report that (i) the combined treatment of Aur and DSF results in synergistic cytotoxicity to hepatoma cells in vitro and in vivo; (ii) Aur and DSF in combination induces caspase activation, endoplasmic reticulum (ER) stress, and reactive oxygen species (ROS) production; (iii) pan-caspase inhibitor z-VAD-FMK could efficiently block apoptosis but not proteasome inhibition induced by Aur and DSF combined treatment, and ROS is not required for Aur+DSF to induce apoptosis. Collectively, we demonstrate a model of synergism between DSF and proteasomeassociated DUB inhibitor Aur in the induction of apoptosis in hepatoma cancer cells, identifying a potential novel anticancer strategy for clinical use in the future.

KW - Anticancer strategy

KW - Auranofin

KW - Deubiquitinase inhibitor

KW - Disulfiram

UR - http://www.scopus.com/inward/record.url?scp=84962257048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962257048&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.6425

DO - 10.18632/oncotarget.6425

M3 - Article

VL - 7

SP - 2796

EP - 2808

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 3

ER -